Uploaded October 2026 | Updated November 2026, 4 days ago
Some people are born with a PCSK9 gene that doesn't work, and they have low LDL cholesterol their whole lives. VERVE-102, a base editor from Eli Lilly's Verve, tries to copy that with one infusion. It changes a single DNA letter in liver cells to switch PCSK9 off, without cutting through both DNA strands. In the Phase 1 Heart-2 trial (NEJM 2026), the 7 people on the top dose (1.0 mg/kg, about 0.45 mg/lb) saw LDL fall 62% on average and PCSK9 fall 88%. Across dose groups, the drops held for at least a year in 15 people, with follow-up up to 18 months. This is an early trial: it has not shown fewer heart attacks, long-term safety needs more follow-up, and VERVE-102 is not approved.
Sources:
nejm.org/doi/full/10.1056/NEJMoa2601283
investor.lilly.com/news-releases/news-release-details/single-dose-lillys-pcsk9-base-editor-verve-102-reduced-pcsk9-88
discovery.ucl.ac.uk/id/eprint/10226555/1/Humphries_Heart-2%20NEJM%20Ms%20DRAFT%209.pdf
pubmed.ncbi.nlm.nih.gov/16554528
#cholesterol #geneediting #medicine #biotech #science #shorts #Shorts
Some people are born with a PCSK9 gene that doesn't work, and they have low LDL cholesterol their whole lives. VERVE-102, a base editor from Eli Lilly's Verve, tries to copy that with one infusion. It changes a single DNA letter in liver cells to switch PCSK9 off, without cutting through both DNA strands. In the Phase 1 Heart-2 trial (NEJM 2026), the 7 people on the top dose (1.0 mg/kg, about 0.45 mg/lb) saw LDL fall 62% on average and PCSK9 fall 88%. Across dose groups, the drops held for at least a year in 15 people, with follow-up up to 18 months. This is an early trial: it has not shown fewer heart attacks, long-term safety needs more follow-up, and VERVE-102 is not approved.
Sources:
nejm.org/doi/full/10.1056/NEJMoa2601283
investor.lilly.com/news-releases/news-release-details/single-dose-lillys-pcsk9-base-editor-verve-102-reduced-pcsk9-88
discovery.ucl.ac.uk/id/eprint/10226555/1/Humphries_Heart-2%20NEJM%20Ms%20DRAFT%209.pdf
pubmed.ncbi.nlm.nih.gov/16554528
#cholesterol #geneediting #medicine #biotech #science #shorts #Shorts










